tradingkey.logo

BRIEF-Vigil Neuroscience Reports Positive Data From Its Phase 1 Clinical Trial

ReutersJan 23, 2025 12:12 PM

- Vigil Neuroscience Inc VIGL.O:

  • VIGIL NEUROSCIENCE REPORTS POSITIVE DATA FROM ITS PHASE 1 CLINICAL TRIAL EVALUATING VG-3927 FOR THE POTENTIAL TREATMENT OF ALZHEIMER’S DISEASE

  • VIGIL NEUROSCIENCE INC - VG-3927 TO ADVANCE TO PHASE 2 TRIAL IN Q3 2025

  • VIGIL NEUROSCIENCE INC - VG-3927 ACHIEVED UP TO 50% REDUCTION OF STREM2 IN CSF

  • VIGIL NEUROSCIENCE INC - VG-3927 SHOWED FAVORABLE SAFETY AND TOLERABILITY PROFILE

Source text: ID:nGNXqgh0d

Further company coverage: VIGL.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI